TERT promoter mutations were significantly more frequent among male patients as compared to their female counterparts with melanoma (49%, n = 638/1298 vs. 35%, n = 328/945, respectively) (OR = 1.82; 95%CI, 1.53-2.16; Q < .001), HPBC (17%, n = 137/827 vs. 4.9%, n = 36/741, respectively) (OR = 3.89; 95%CI, 2.65-5.69; Q < .001), cancer of unknown primary (11%, n = 116/1065 vs. 5.9%, n = 64/1081, respectively) (OR = 1.96; 95%CI, 1.43-2.69; Q < .001), and thyroid cancer (46%, n = 213/468 vs. 37%, n = 182/491, respectively) (OR = 1.42; 95%CI, 1.10-1.84; Q = .017). Here, TERT is linked to melanoma.